2024-11-27 08:21:26
Innovent Announces First Patient Dosing in Australia in Phase I Study of IBI343 (Recombinant anti-Claudin18.2 Monoclonal Antibody-drug Conjugate) in Patients with Advanced Solid Tumors
Corporate/ 2023-07-24
Innovent Announces First Patient Dosing ...

ROCKVILLE,Md. and SUZHOU,China,Oct. 30,2022-- Innovent Biologics,Inc. ("Innovent") (HKEX: 01801),a world-class biopharmaceutical c...

Akeso Announces Oral Presentation of Ivonescimab (PD-1/VEGF Bi-Specific) in First-line Treatment of ES-SCLC on ACLC 2022
Corporate/ 2023-07-24
Akeso Announces Oral Presentation of Ivo...

HONG KONG,Oct. 31,2022--Akeso,Biopharma (9926. HK) ("Akeso") released the Phase Ib clinical results of Ivonescimab (PD-1/VEGF bi-s...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release